Patients Caught in Crossfire: Insurers Siphon Drug Aid, Leaving Soaring Bills

Patients grappling with chronic illnesses are facing a renewed financial squeeze as many health insurers continue to deploy 'copay accumulator programs' that effectively seize drug manufacturers' financial aid, leaving patients with unexpected and often insurmountable bills. Despite a recent court ruling challenging these practices, federal enforcement remains stalled, forcing vulnerable individuals to choose between vital medication and financial stability. This contentious practice, where patient assistance doesn't count towards deductible, is quietly widespread, catching many off guard. These programs, often managed by Pharmacy Benefit Managers (PBMs), allow insurers to accept copay assistance from pharmaceutical companies but prevent those funds from counting towards a patient's annual deductible or out-of-pocket maximum, essentially 'double-dipping' at the patient's expense. This shifts thousands of dollars in costs back to patients, with annual out-of-pocket expenses for some rising by $4,000 to $4,200, severely impacting those with high-cost specialty medications for conditions like cancer, diabetes, or autoimmune disorders. While 28 states, Washington D.C., and Puerto Rico have enacted laws restricting copay accumulators as of July 2026, these protections often exclude the majority of commercially insured individuals covered by self-funded employer plans. The ongoing legal and legislative tug-of-war is far from over. Congress, through the House Appropriations Committee, recently urged the Centers for Medicare and Medicaid Services (CMS) to clarify guidance on these policies, indicating growing federal scrutiny. Patient advocacy groups continue to push for the bipartisan HELP Copays Act to fully ban these practices nationwide. However, without comprehensive federal action extending to all health plans, millions of patients will remain in the dark and vulnerable to these programs, making transparency and proactive checking of plan details more critical than ever.